State-Level Vaccine Policies and Implications for COVID-19 Vaccination

In the early 2025-26 respiratory virus season in the United States, the lack of updated national vaccine recommendations for COVID-19 presented significant challenges. This was compounded by guidance from the U.S. Health and Human Services Secretary, advising against COVID vaccinations for children and pregnant women, resulting in varied state-level responses. According to a research letter published in JAMA, these responses might have long-term implications for vaccine policy nationwide.

A research team from the University of North Carolina at Chapel Hill evaluated vaccine policy actions across all 50 states from April to December 2025. The study categorized state actions as either reinforcing or reducing COVID-19 vaccine infrastructure and access. This distinction was based on how states responded to the absence of timely federal vaccine recommendations.

The role of regulatory bodies such as the U.S. FDA, ACIP, and CDC is crucial in shaping state regulations regarding healthcare providers, insurance coverage, and vaccine availability. During the assessment period, 31 states implemented policies to bolster vaccine infrastructure or access, while 13 states enacted measures that weakened it. Notably, pharmacy access to vaccines remained a key focus during federal guidance delays.

States enhancing vaccine infrastructure represented approximately 57.9% of the U.S. population, according to 2025 census data. Those enacting measures diminishing infrastructure and access accounted for 25%, and states with mixed policies constituted 6.9%, while the remainder did not take any action. Common strategies to enhance vaccine access included standing orders, insurance directives, and expanded pharmacist authority, reflecting a trend towards leveraging pharmacy networks for vaccine distribution.

Some states issued independent COVID-19 vaccine recommendations, frequently informed by professional organizations such as the American Academy of Pediatrics and the American College of Obstetricians and Gynecologists. Collaborative initiatives, like the Governors Public Health Alliance, also influenced state vaccine policy responses and demonstrated the need for coordinated efforts.

Conversely, policies that limited vaccine infrastructure often altered requirements, influencing informed consent and financial accessibility, with a notable shift towards prioritizing individual health over population health considerations. Amid the absence of updated federal recommendations, as of January 2026, 28 states announced plans to rely on clinical guidance from national medical societies instead of solely following CDC guidelines.

The findings emphasize the impact of diverse state policies on vaccine access and distribution in the face of evolving federal guidance. This situation underscores the importance of stable, evidence-based guidance to ensure consistent vaccine availability and administration across the U.S. healthcare system.